New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 25, 2014
08:18 EDTAZN, BCSAstraZeneca, Barclays investors push back on executive pay, Telegraph says
38.5% of AstraZeneca (AZN) shareholders voted against the company's executive pay plan, while 24% of investors voted against Barclays' (BCS) pay plan, reported The Telegraph. "We are disappointed with today's vote. As a priority we will be seeking to understand what concerns lay behind this," said an AstraZeneca spokesman. Reference Link
News For AZN;BCS From The Last 14 Days
Check below for free stories on AZN;BCS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 16, 2014
07:31 EDTAZNEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
07:02 EDTAZNEli Lilly and AstraZeneca to co-develop and commercialize AZD3293
Subscribe for More Information
06:27 EDTAZNAstraZeneca, Eli Lilly to jointly develop, commercialize AZD3293
AstraZeneca (AZN) and Eli Lilly (LLY) announced an agreement to jointly develop and commercialize AZD3293, an oral beta secretase cleaving enzyme inhibitor currently in development as a potential treatment for Alzheimer's disease. AZD3293 has been shown in Phase I studies to significantly and dose-dependently reduce levels of amyloid beta in the cerebro-spinal fluid of Alzheimer's patients and healthy volunteers. AstraZeneca announced earlier in 2014 its plan to move AZD3293 into registration trials. Under the terms of the agreement, Lilly will pay AstraZeneca up to $500M in development and regulatory milestone payments. AstraZeneca expects to receive the first milestone payment of $50M in the 1H15. The companies will share all future costs equally for the development and commercialization of AZD3293, as well as net global revenues post-launch. AstraZeneca and Lilly aim to progress AZD3293 rapidly into a Phase II/III clinical trial in patients with early Alzheimer's disease. Lilly will lead clinical development, working with researchers from AstraZeneca's Innovative Medicines Unit for neuroscience, while AstraZeneca will be responsible for manufacturing. The companies will take joint responsibility for commercialization of AZD3293. The agreement is subject to customary terms and conditions. It will have no impact on AstraZeneca's 2014 Core Earnings per Share.
September 15, 2014
07:49 EDTBCSDOJ, FBI 'flip' bank informants as part of forex probe, WSJ says
Subscribe for More Information
07:27 EDTAZNPfizer acquisition could drive shares higher, says JPMorgan
Subscribe for More Information
September 12, 2014
10:32 EDTAZNPfizer CEO says company still open to inversion deal, FT says
Pfizer (PFE) CEO Ian Read said U.S. rhetoric against tax inversions has been "political theater" ahead of midterm elections and made clear that his company is still open to a potential tax-saving acquisition, according to Financial Times, which added Read's comment about not being “held hostage” over price would likely be read as a signal the company might look elsewhere after being rebuffed by AstraZeneca (AZN). The Fly notes that Bloomberg previously reported, citing people familiar with the matter, that Pfizer is looking at targets other than AstraZeneca, including Actavis (ACT). Shares of Actavis trading in New York are up 2% this morning. Reference Link
06:48 EDTBCSU.K. bankers worry that Britain could leave EU, NY Times says
Subscribe for More Information
06:08 EDTBCSAviva names Adrian Montague as chairman, effective April 2015
Subscribe for More Information
06:06 EDTBCSBarclays says John McFarlane to succeed David Walker as chairman
Subscribe for More Information
September 10, 2014
15:21 EDTAZNAstraZeneca has a conference call hosted by JPMorgan
Subscribe for More Information
06:20 EDTBCSBarclays hires BofA Merrill Lynch's Richard Casavechia, FT reports
Subscribe for More Information
September 9, 2014
11:59 EDTBCSBarclays narrows bidders for index unit to Markit, S&P, Reuters says
Barclays (BCS) has narrowed the list of bidders for its Index, Portfolio and Risk Solutions business, which could fetch more than $1B, to Markit (MRKT) and McGraw Hill Financial's (MHFI) Standard & Poor's unit, according to Reuters, citing people familiar with the matter. MSCI (MSCI) and privately-held Bloomberg had also expressed interest, according to the report. Reference Link
10:10 EDTBCSOn the Fly: Analyst Upgrade Summary
Subscribe for More Information
05:26 EDTBCSBarclays upgraded to Overweight from Neutral at HSBC
Subscribe for More Information
September 8, 2014
14:13 EDTAZNConnecticut AG tells FDA to speed up generic Nexium
A news release from the Connecticut Attorney General George Jepsen, dated September 4, says: In comments to a Citizen Petition filed with the FDA, Attorney General George Jepsen called on the federal agency to expeditiously end several years of delays preventing the sale of a generic form of the drug esomeprazole magnesium , esomeprazole, currently marketed under the brand name Nexium. Nexium is the second highest-selling pharmaceutical drug in the United States, and delays in approving generic versions have cost consumers and government healthcare payers billions of dollars. In his comments, Attorney General Jepsen alleges that an agreement between drug manufacturers Ranbaxy (RBXLY) and AstraZeneca Pharmaceuticals (AZN), Nexium’s brand-name manufacturer, has prevented other drug-makers from launching a generic version of the drug, ultimately harming all consumers by artificially inflating prices. Ranbaxy was first-to-file with the FDA for approval of a generic form of Nexium. AstraZeneca sued Ranbaxy for patent infringement, and the dispute was settled by an agreement that provided financial incentives for Ranbaxy to delay entry of its generic into the consumer market. Reference Link
13:32 EDTBCSBarclays exec says 2,700 jobs eliminated so far this year, Reuters says
Barclays investment bank CEO Tom King said that the company has reduced its staff members by 2,700 so far this year in an effort to comply with its plan to cut 7K positions through 2017, according to Reuters, citing comments from King. Reference Link
07:02 EDTAZNAstraZeneca announces availability of Bydureon pen 2mg
Subscribe for More Information
September 5, 2014
07:18 EDTBCSRegulators drafting flexible 'bail in' bond deal for large banks, Reuters says
Subscribe for More Information
06:23 EDTBCSBarclays to launch biometric fingre vein readers for clients, FT reports
Subscribe for More Information
06:22 EDTBCSUBS, Barclays postpone hiring due to stricter background checks, Bloomberg says
UBS (UBS) and Barclays (BCS) have decreased their job opportunities and postponed start dates in response to some banks strengthening background examinations, after past offenses increased the need for more investigative research on the behavior of individuals, according to Bloomberg, citing three people with knowledge of the situation. Reference Link
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use